Bavarian Nordic Beheer

Beheer criteriumcontroles 3/4

De CEO Bavarian Nordic is Paul Chaplin, benoemd in Jun2014, heeft een ambtstermijn van 10.42 jaar. De totale jaarlijkse vergoeding van { bedraagt DKK 23.43M, bestaande uit 30.7% salaris en 69.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.11% van de aandelen van het bedrijf, ter waarde DKK 14.31M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.8 jaar en 3.8 jaar.

Belangrijke informatie

Paul Chaplin

Algemeen directeur

DKK 23.4m

Totale compensatie

Percentage CEO-salaris	30.7%
Dienstverband CEO	10.4yrs
Eigendom CEO	0.1%
Management gemiddelde ambtstermijn	4.8yrs
Gemiddelde ambtstermijn bestuur	3.8yrs

Recente managementupdates

Recent updates

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

Nov 16

Market Participants Recognise Bavarian Nordic A/S' (CPH:BAVA) Earnings Pushing Shares 53% Higher

Aug 26

Bavarian Nordic A/S Just Missed Earnings - But Analysts Have Updated Their Models

Aug 25

Bavarian Nordic (CPH:BAVA) Seems To Use Debt Quite Sensibly

Aug 09

Bavarian Nordic A/S' (CPH:BAVA) Shareholders Might Be Looking For Exit

Jul 11

Results: Bavarian Nordic A/S Delivered A Surprise Loss And Now Analysts Have New Forecasts

May 12

Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet

Apr 09

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

Feb 26

Bavarian Nordic A/S' (CPH:BAVA) Business And Shares Still Trailing The Industry

Jan 03

Bavarian Nordic A/S (CPH:BAVA) Shares Could Be 45% Below Their Intrinsic Value Estimate

Dec 10

Here's Why Bavarian Nordic (CPH:BAVA) Can Manage Its Debt Responsibly

Nov 15

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

Aug 17

Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet

Apr 19

Is Bavarian Nordic (CPH:BAVA) Weighed On By Its Debt Load?

Jan 03

Bavarian Nordic (CPH:BAVA) Has Debt But No Earnings; Should You Worry?

Sep 15

Analyse CEO-vergoeding

Hoe is Paul Chaplin's beloning veranderd ten opzichte van Bavarian Nordic's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	DKK 1b
Jun 30 2024	n/a	n/a	DKK 707m
Mar 31 2024	n/a	n/a	DKK 984m
Dec 31 2023	DKK 23m	DKK 7m	DKK 1b
Sep 30 2023	n/a	n/a	DKK 723m
Jun 30 2023	n/a	n/a	DKK 1b
Mar 31 2023	n/a	n/a	DKK 301m
Dec 31 2022	DKK 22m	DKK 6m	-DKK 347m
Sep 30 2022	n/a	n/a	-DKK 599m
Jun 30 2022	n/a	n/a	-DKK 693m
Mar 31 2022	n/a	n/a	-DKK 606m
Dec 31 2021	DKK 18m	DKK 6m	-DKK 465m
Sep 30 2021	n/a	n/a	-DKK 737m
Jun 30 2021	n/a	n/a	-DKK 629m
Mar 31 2021	n/a	n/a	-DKK 368m
Dec 31 2020	DKK 14m	DKK 5m	DKK 278m
Sep 30 2020	n/a	n/a	DKK 606m
Jun 30 2020	n/a	n/a	DKK 481m
Mar 31 2020	n/a	n/a	DKK 267m
Dec 31 2019	DKK 12m	DKK 5m	-DKK 347m
Sep 30 2019	n/a	n/a	-DKK 402m
Jun 30 2019	n/a	n/a	-DKK 271m
Mar 31 2019	n/a	n/a	-DKK 279m
Dec 31 2018	DKK 12m	DKK 6m	-DKK 362m
Sep 30 2018	n/a	n/a	-DKK 445m
Jun 30 2018	n/a	n/a	-DKK 151m
Mar 31 2018	n/a	n/a	DKK 5m
Dec 31 2017	DKK 13m	DKK 5m	DKK 181m

Compensatie versus markt: De totale vergoeding ($USD 3.31M ) Paul } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Danish markt ($USD 1.97M ).

Compensatie versus inkomsten: De vergoeding van Paul is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Paul Chaplin (57 yo)

10.4yrs

Tenure

DKK 23,428,000

Compensatie

Dr. Paul John Chaplin, M.Sc., Ph D., has been the Chief Executive Officer and President at Bavarian Nordic A/S since May 28, 2014. Dr. Chaplin served as an Executive Vice President of Bavarian Nordic A/S f...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Paul Chaplin	CEO & President	10.4yrs	DKK 23.43m	0.11% DKK 14.3m
Henrik Juuel	CFO & Executive VP	6yrs	DKK 12.23m	geen gegevens
Russell Thirsk	Executive VP & COO	2.6yrs	geen gegevens	geen gegevens
Rolf Sørensen	Vice President of Investor Relations & Communications	no data	geen gegevens	geen gegevens
Anu Kerns	Executive VP and Chief People & Sustainability Officer	4yrs	geen gegevens	geen gegevens
Jean-Christophe May	Executive VP & Chief Commercial Officer	4.8yrs	geen gegevens	geen gegevens

4.8yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van BAVA wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Peter Kürstein-Jensen	Independent Director	12.6yrs	DKK 740.00k	0.026% DKK 3.5m
Anders Pedersen	Deputy Chairman	14.6yrs	DKK 1.13m	0.024% DKK 3.2m
Franciscus A. G. Verwiel	Independent Director	8.6yrs	DKK 830.00k	0.0055% DKK 729.2k
Anne Eberhard	Independent Director	5.6yrs	DKK 860.00k	0.0034% DKK 458.2k
Luc Debruyne	Independent Chairman	1.7yrs	DKK 1.43m	geen gegevens
Heidi Hunter	Independent Director	1.8yrs	DKK 635.00k	geen gegevens
Linette Munksgaard Andersen	Employee-Elected Member of the Board	3.8yrs	DKK 475.00k	0.00070% DKK 93.0k
Thomas Alex Bennekov	Employee-Elected Member of the Board	3.8yrs	DKK 475.00k	0.0024% DKK 314.8k
Anja Gjol	Employee-Elected Member of the Board	3.8yrs	DKK 475.00k	0.00070% DKK 93.0k
Karen Merete Jensen	Employee-Elected Member of the Board	3.8yrs	DKK 475.00k	0.00062% DKK 82.3k
Johan Hoof	Independent Director	1.8yrs	DKK 575.00k	geen gegevens
Montse Picart	Independent Director	less than a year	geen gegevens	geen gegevens

3.8yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van BAVA wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Bavarian Nordic Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

CEO & President recently sold kr.24m worth of stock

CEO & President exercised options to buy kr.24m worth of stock.

Bavarian Nordic A/S, Annual General Meeting, Apr 09, 2025

Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer

Deputy Chairman exercised options to buy kr.123k worth of stock.

CEO & President exercised options to buy kr.1.4m worth of stock.

Recent updates

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

Investor sentiment deteriorates as stock falls 18%

First Children Vaccinated in New Clinical Study Seeking to Expand the Indication for Bavarian Nordic's Mpox Vaccine

Bavarian Nordic A/S Upgrades Earnings Guidance for the Year 2024

Price target increased by 9.0% to kr.312

Bavarian Nordic A/S Receives EMA Approval of Mpox Vaccine for Adolescents

Bavarian Nordic Receives WHO Prequalification for Mpox Vaccine

CEO & President recently sold kr.24m worth of stock

CEO & President exercised options to buy kr.24m worth of stock.

Bavarian Nordic A/S Announces First Doses of its Mpox Vaccine, Mva-BN

Consensus EPS estimates increase by 56%

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Singapore

Market Participants Recognise Bavarian Nordic A/S' (CPH:BAVA) Earnings Pushing Shares 53% Higher

Bavarian Nordic A/S Just Missed Earnings - But Analysts Have Updated Their Models

Price target increased by 8.7% to kr.286

Second quarter 2024 earnings: Revenues exceed analyst expectations

Bavarian Nordic A/S, Annual General Meeting, Apr 09, 2025

Bavarian Nordic A/S to Report Fiscal Year 2024 Results on Mar 05, 2025

New major risk - Share price stability

Bavarian Nordic A/S Submits Data to EMA to Extend Mpox/Smallpox Vaccine Approval to Adolescents

Investor sentiment improves as stock rises 18%

Bavarian Nordic (CPH:BAVA) Seems To Use Debt Quite Sensibly

Bavarian Nordic A/S Receives Positive Chmp Opinion for Including Mpox Real-World Effectiveness Data in European Marketing Authorization for Smallpox and Mpox Vaccine

Bavarian Nordic A/S Receives EMA Filing Acceptance and Validation of the MAA for Its Chikungunya Vaccine

Bavarian Nordic A/S' (CPH:BAVA) Shareholders Might Be Looking For Exit

Bavarian Nordic A/S Submits Marketing Authorization Application for Its Chikungunya Vaccine Candidate to Ema

Investor sentiment improves as stock rises 18%

Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer

Results: Bavarian Nordic A/S Delivered A Surprise Loss And Now Analysts Have New Forecasts

First quarter 2024 earnings released: kr.1.50 loss per share (vs kr.5.10 profit in 1Q 2023)

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024

Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate

Deputy Chairman exercised options to buy kr.123k worth of stock.

Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

CEO & President exercised options to buy kr.1.4m worth of stock.

Full year 2023 earnings released: EPS: kr.19.20 (vs kr.4.93 loss in FY 2022)

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

Price target increased by 9.4% to kr.293

Bavarian Nordic A/S' (CPH:BAVA) Business And Shares Still Trailing The Industry

Bavarian Nordic A/S (CPH:BAVA) Shares Could Be 45% Below Their Intrinsic Value Estimate

Third quarter 2023 earnings released: kr.4.40 loss per share (vs kr.0.20 profit in 3Q 2022)

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Here's Why Bavarian Nordic (CPH:BAVA) Can Manage Its Debt Responsibly

Bavarian Nordic A/S's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk

Investor sentiment improves as stock rises 15%

Bavarian Nordic A/S Reports Additional Phase 3 Results and Provides Update on Development Program for its cVLP-Based COVID-19 Booster Vaccine Candidate, ABNCoV2

Bavarian Nordic A/S, Annual General Meeting, Apr 16, 2024

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Bavarian Nordic A/S Provides Update on RSV Vaccine Program

Investor sentiment deteriorates as stock falls 26%

Bavarian Nordic A/S Reports Data from A Phase 3 Clinical Trial of Its Vlp-Based Chikungunya Virus Vaccine in Adults >=65 Years of Age Study Successfully Met Its Primary Endpoints

Bavarian Nordic A/S Reports 12-Month Durability Data from Phase 2 Clinical Trial of Covid-19 Vaccine Candidate

Consensus EPS estimates increase by 40%

Bavarian Nordic A/S acquired Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $384 million.

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet

Full year 2022 earnings released: kr.4.90 loss per share (vs kr.7.37 loss in FY 2021)

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S Provides Earnings Guidance for Fiscal Year 2023

Bavarian Nordic A/S Provides Revenue Guidance for Fiscal Year 2022

Is Bavarian Nordic (CPH:BAVA) Weighed On By Its Debt Load?

Bavarian Nordic Completes Enrollment in Global Phase 3 Trial of RSV Vaccine Candidate for Older Adults

Chairman recently sold kr.508k worth of stock